1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Breast Cancer Therapeutics Industry: Forecasts to 2023

  • November 2015
  • 88 pages
  • ID: 3516804
In this report:
The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future.

Summary

Table of Contents

This market report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report contain pharmaceutical companies and intermediaries involved in the additional drug discovery, pipeline development of different breast cancer therapeutics as well as additional entrants planning to enter this sector. This business report comprises a detailed executive summary together with a market snapshot providing global information of several segments and subsegments considered in the coverage of the report. This section also offers the global information and data analysis of the overall breast cancer therapeutics market with respect to the leading market segments in terms of geography.

The overall breast cancer therapeutics market has been studied based on main drug class segments, and their regional as well as national markets. Established on drug class, the worldwide market has been classified into five main segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The sector for these segments and subsegments has been comprehensively studied based on their utility, effectiveness, sales, and geographic presence. Market income in terms of US$ Mn and CAGR from 2015 to 2023 are provided for all segments, considering 2014 as the base year.

The section 'market overview' of this report explores the market dynamics including drivers, market restraints, and alternatives that currently have a strong impact on the breast cancer therapeutics market and could influence the industry in the upcoming future. Analysis of market appeal has been specified in the market survey part in order to explain the intensity of competition in the sector across various areas. The challenging scenario among distinct market players is illustrated through market share review in the ambitious landscape section of the report. All these aspects would benefit market actors to take tactical decisions in order to enhance their positions and expand their shares in the overall market.

Geographically, the breast cancer therapeutics market has been divided into five regions: North America continent (the U.S.A and Canada (CA)), EU (the United Kingdom, Germany (DE), and Rest of Europe (EU)), Asia Pacific (APAC) (Japan (JP), South Korea, and Rest of APAC), Latin America area (Brazil (BR) and Rest of Latin America area), and Middle East (ME) & African continent. Market income in terms of US$ Mn and Compound annual growth rate % from 2015 to 2023 are provided for all the areas and territories, considering 2014 as the base year.

The recommendations section included in the market research would assist existing market players in expanding their market shares and additional pharmaceutical companies in establishing their presence in the overall breast cancer market. The report also profiles leading and emerging additional players in the breast cancer therapeutics segment based on several features such as corporate overview and financial analysis, strategic management, product portfolio, and recent evolutions. Main actors described in this study include AstraZeneca plc, Eisai Co., Limited, Eli Lilly and Organization, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Incorporated, Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The overall breast cancer therapeutics segment has been split as follows:

Overall Breast Cancer Therapeutics Market, by Drug Class

Summary

Overall HER2 Inhibitors Market Revenue, 2015-2023

Overall Mitotic Inhibitors Market Revenue, 2015-2023

Overall Anti-metabolites Market Revenue, 2015-2023

Gemzar

Overall Aromatase Inhibitors Market Revenue, 2015-2023

Overall Hormone Receptor Market Revenue, 2015-2023

Overall Breast Cancer Therapeutics Market, by Geography

North America (NA)

USA

Canada (CA)

Europe (EU)

Germany (DE)

United Kingdom (UK)

Asia-Pac

Japan (JP)

South Korea (KR)

Rest of Asia Pacific (APAC)

Latin America

Brazil (BR)

Rest of Latin America

African region & Middle East

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Pipeline Review, H2 2018SummaryAccording to the recently published report ...

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2018

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2018

  • $ 3500
  • November 2018

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2018SummarySerine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 ...

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 2018

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 2018

  • $ 3500
  • November 2018

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 2018SummaryAccording to the recently published report ’SerineThreonine Protein Kinase Pim 3 - Pipeline ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on